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Abstract:  CD36  has  been  associated  with  obesity  and  diabetes  in  human  liver  diseases,  however,  its  role  in  age‐
associated nonalcoholic fatty liver disease (NAFLD) is unknown. Therefore, liver biopsies were collected from individuals
with histologically normal  livers (n=30), and from patients diagnosed with simple steatosis (NAS; n=26). Patients were
divided  into two groups according to age and  liver biopsy samples were  immunostained for CD36. NAFLD parameters
were examined in young (12‐week) and middle‐aged (52‐week) C57BL/6J mice, some fed with chow‐diet and some fed
with  low‐fat  (LFD;  10%  kcal  fat)  or  high‐fat  diet  (HFD;  60%  kcal  fat)  for  12‐weeks.  CD36  expression  was  positively
associated  with  age  in  individuals  with  normal  livers  but  not  in  NAS  patients.  However,  CD36  was  predominantly
located at the plasma membrane of hepatocytes in aged NAS patients as compared to young. In chow‐fed mice, aging,
despite an increase in hepatic CD36 expression, was not associated with the development of NAFLD. However, middle‐
aged mice did exhibit  the development of HFD‐induced NAFLD, mediated by an  increase of CD36 on  the membrane.
Enhanced  CD36‐mediated  hepatic  fat  uptake  may  contribute  to  an  accelerated  progression  of  NAFLD  in  mice  and
humans.  Therapies  to  prevent  the  increase  in  CD36  expression  and/or  CD36  from  anchoring  at  the membrane may
prevent the development of NAFLD.  
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INTRODUCTION  
 
The world is experiencing a dramatic increase in 
numbers of elderly people, rising to an estimated 22% 
of the world population aged 60 years and older by 
2050 [1]. Although population aging is an indicator of 
improving global health, it has also become one of the 
century's main health problems. Aging is the leading 
risk factor for all chronic diseases, accounting for 60% 
of all deaths worldwide [2]. Thus, to understand how 
aging increases susceptibility to disease is vital in order 
to sustain a healthy aging society.  
 
Nonalcoholic fatty liver disease (NAFLD) is, 
worldwide, the most common liver disease, affecting 
one-third of the overall population [3]. NAFLD includes 
a wide spectrum of liver pathologies progressing from 
benign hepatic steatosis, to nonalcoholic-steatohepatitis 
(NASH), severe cirrhosis and fibrosis [4]. Growing 
evidence points towards an increased prevalence of 
NAFLD in older humans [5]. Indeed, aging is 
associated with a physiological increase in lipid 
accumulation in non-adipose tissues, including the liver 
[6]. Moreover, aging is associated with increased 
mortality in elderly subjects with NAFLD by 
significantly enhancing the progression to NASH and 
fibrosis [7,8]. Although fat may accumulate in the liver 
as a result of multiple abnormalities of hepatic lipid 
accumulation [9], few studies have examined the effect 
of aging on hepatic lipid metabolism [10–14]. As not all 
study outcomes share a common view on the impact of 
aging on NAFLD development [14], the cellular 
mechanisms underlying this age-related fat overload in 
the liver remain ill-defined. 
 
CD36 facilitates the uptake of long-chain fatty acids 
(LCFA) across the cell membrane and high levels of 
expression can contribute to lipid accumulation in 
heart and skeletal muscle [15]. Enhanced efficiency of 
LCFA uptake is directly related to increased 
recruitment of CD36 from intracellular storage sites 
into the plasma membrane. Increased CD36 expression 
in human and rodent models is commonly related to 
insulin resistance and type 2 diabetes, including high-
fat (HF) feeding and obesity [16–18] and is also 
observed in the physiological aging process [19–21]. 
In the liver, CD36 was long believed to play a very 
minor role in LCFA uptake [15]. Diets rich in fatty 
acids have, however, been shown to increase protein 
expression of CD36 in the liver [18]. Moreover, as we 
have previously observed, LCFA uptake and lipid 
deposition in the liver are directly related to CD36 
expression, suggesting a causative role for increased 
CD36 expression in the pathogenesis of type 2 
diabetes [18]. Similar findings were observed by 
several other rodent studies [22,23] and have recently 
been confirmed in liver biopsies of patients with 
NAFLD, highlighting the clinical relevance of CD36 
in human liver diseases associated with obesity and 
type 2 diabetes [24]. Its role in age-associated NAFLD 
is, however, not yet known. 
 
We have, therefore, sought to investigate whether 
increased CD36 expression underlies the increased 
susceptibility to the development of NAFLD with age. 
Our data show that aging is associated with a dramatic 
increase in CD36 expression in human NAFLD as well 
as in aged mice on a normal diet. Our data also show 
that aging, in combination with HF-feeding, triggers the 
presence of CD36 at the cell surface of hepatocytes, 
which may contribute to enhanced fat uptake in NAFLD 
and drive the progression of simple steatosis towards 
NASH. Therefore, our data suggest that therapies to 
prevent the increase in CD36 expression and CD36 
from anchoring at the membrane may prevent the 




Hepatic CD36 expression profile in humans  
 
To determine whether CD36 expression in the human 
liver is increased by the physiological process of aging, 
immunohistochemical staining for CD36 was performed 
in liver biopsy samples from young (20-38 years) and 
aged individuals (50-83 years) with histologically 
normal livers, and liver biopsy samples from young (20-
42 years) and aged individuals (52-74 years) diagnosed 
with non-alcoholic steatosis (NAS) (Fig. 1A). We 
observed a significant increase in the percentage of liver 
tissue expressing CD36 in aged versus young normal 
liver sections, suggesting an association between aging 
and increased CD36 expression in the healthy human 
liver (Fig. 1B). Furthermore, this increase in CD36 
expression in the healthy human liver was directly 
correlated with age, as shown by linear regression 
analysis of all normal human liver samples (Fig. 1C; 
r2=0.97). Aged subjects with normal livers had 
significant increases in glucose levels, waist perimeters, 
aspartate aminotransferase and alkaline phosphatase 
when compared to young subjects (Table 1, p<0.05). 
However, no differences were observed in body mass 
index, hip perimeter, plasma lipids, insulin, alanine 
aminotransferase and gamma-glutamyltransferase 
between young and aged subjects with normal livers 
(Table 1). When comparing subjects having normal 
livers with NAS patients, we also observed in the latter 
a significant increase in the hepatic CD36 expression 
index in both young and old (Fig. 1B). However, there 
was in NAS patients no age-based difference in the 
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CD36 expression (Fig. 1B), suggesting that absolute 
CD36 protein expression levels in steatotic livers do not 
correlate with age. Indeed, linear regression analysis 
confirmed the absence of an age effect on CD36 
expression in NAS livers (Fig. 1C; r2=0.12). Further-
more, CD36 was largely confined to the cytoplasm of 
most hepatocytes in both young and aged healthy 
human liver biopsies (Fig. 1A, upper panels, inserts). 














































cytoplasm of hepatocytes of young NAS patients (Fig. 
1A, left lower panel, insert). This in contrast to aged 
steatotic livers, where CD36 was located predominantly 
at the plasma membrane of hepatocytes (Fig. 1A, right 
lower panel, insert), suggesting that aging may 
significantly enhance CD36 translocation in steatotic 
livers. From a clinical point of view, characteristics of 
young and aged NAS patients were not significantly 















































Figure  1.  CD36  expression  is  positively  associated  with  age  in  liver  biopsies  from
patients with normal  livers, but not  in  liver biopsies  from patients with non‐alcoholic
steatosis (NAS). (A) CD36 immunostaining of liver biopsy tissue from: young normal liver, 29 years
old  (Left  upper  panel),  old  normal  liver,  76  years  old  (Right  upper  panel),  young  non‐alcoholic
steatosis (NAS), 31 years old (Left  lower panel), old NAS, 75 years old (Right  lower panel). Original
magnification for all microphotographs: 400x. Each microphotograph includes a 2x zoom detail. (B)
Hepatic  CD36  expression  index  in  liver  biopsies  from  patients  with  normal  livers  and  NAS.  (C)
Correlation between age and hepatic CD36 expression index in normal livers and NAS.  
  

















































































































 Normal liver NAS 
 Young (n=16) Aged (n=14) Young (n=11) Aged (n=15) 
Age (years) 29 (20 – 38) 67 (50 – 83)* 33 (24 – 42) 63 (52 – 74)* 
Female gender (%)  16 (100%) 8 (57%) 7 (64%) 7 (47%) 
Body mass index (kg/m2) 25.1 ± 4.3 28.2 ± 5.1 28.3 ± 3.6 30.6 ± 4.1 
Waist Perimeter (cm) 86.9 ± 8.3 98.2 ± 10.3* 99.0 ± 9.5** 105.3 ± 9.7 
Hip Perimeter (cm) 102.3 ± 7.7 104.4 ± 12.1 106.4 ± 8.8 109.7 ± 9.2 
Glucose (mg/dl) 85.8 ± 7.7 94.8 ± 10.4* 88.5 ± 7.2 94.1 ± 8.5 
Insulin (mU/ml) 6.4 ± 4.1 7.1 ± 2.4 9.5 ± 4.7 9.2 ± 4.2 
HOMA-IR 0.8 ± 0.5 0.9 ± 0.3 1.2 ± 0.6 1.2 ± 0.6 
Triglycerides (mg/dl) 84.6 ± 32.8 109.6 ± 52.2 143.6 ± 80.9** 123.1 ± 48.0 
Total Cholesterol (mg/dl) 180.9 ± 26.9 178.7 ± 41.3 207.3 ± 67 200.6 ± 21.4 
HDL-cholesterol (mg/dl) 49.4 ± 8.5 48.5 ± 12.3 48.7 ± 12.3 47.0 ± 10.4 
ALT (IU/L) 14.7± 5.5 19.9 ± 9.1 24.5 ± 11.3** 24.4 ± 10.4 
AST (IU/L) 15.3 ± 3.4 18.8 ± 4.4* 19.7 ± 8.4 21.1 ± 4.3 
-GT (IU/L) 22.7 ± 16.3 33.2 ± 24.7 61.5 ± 79.6 44.9 ± 56.9 
ALP (IU/L) 59.8 ± 18.2 77.7 ± 23.9* 60.7 ± 21.8 79.7 ± 20.5* 
Grade of steatosis      
Grade 0  16 (100%) 14 (100%)   
Grade 1    9 (82%) 10 (62%) 





NAS,  non‐alcoholic  steatosis;  HDL,  high‐density  lipoprotein;  HOMA‐IR,  homeostatic  model  assessment‐insulin 
resistance;  ALT,  alanine  aminotransferase;  AST,  aspartate  aminotransferase;  ‐GT,  gamma‐glutamyltransferase; 
ALP, alkaline phosphatase 
  


















































Aging does not induce hepatic steatosis or 
inflammation in chow-fed mice  
 
To further investigate the correlation between aging and 
hepatic CD36 expression, we assessed CD36 expression 


















































weight was significantly increased (Fig. 2A) in middle-
aged mice and no difference was observed in the liver to 
body weight ratio (data not shown). Hepatic CD36 gene 
(Fig. 2B) and protein expression (Fig. 2C) were 
significantly increased with aging in mice similar to that 
found in normal liver biopsies of aging humans.  
Figure 2. Aging does not trigger the development of hepatic steatosis and inflammation in mice fed a chow diet for one




embedded  liver  sections obtained  from young and middle‐aged mice  fed a chow diet.  (E) Triglyceride  (TG)  levels were determined  in

























































Histological assessment of H&E stained liver sections 
of young and middle-aged mice showed a slight 
occurrence of macrovesicular steatosis in livers of 
middle-aged mice (Fig. 2D). However, hepatic 



















































middle-aged mice did not differ, confirming that lipid 
droplet formation in middle-aged mice was not 
quantitatively relevant. We observed no alterations in 
the expression of several pro-inflammatory cytokines 
and genes encoding for proteins involved in macrophage 
Figure 3. Aging  increases hepatic steatosis and  inflammation  in mice  fed a HFD  for 12 weeks.  (A) Body weight of
young and middle‐aged mice fed a HFD. (B) H&E staining of paraffin embedded liver sections and (C) biochemically quantification
of    liver  triglycerides  (TG) of young and middle‐aged mice  fed a HFD.  (D) mRNA expression of cytokines and genes  involved  in








www.impactaging.com                    286                                          AGING,  April 2014, Vol. 6 No.4
infiltration (Il1β, Tnf, IkBα, Cd68, Mcp1, Cxcl1) in 
middle-aged mice as compared to young mice (Fig. 2F). 
In addition, no difference was observed in the 
inflammatory signaling often associated with NAFLD 
in livers of middle-aged mice, as the phosphorylation 
status of the extracellular signal-regulated kinase 1/2 
(Erk 1/2) was not affected by aging in these mice (Sup. 
Fig. 1A). These data suggest that aging is not associated 
with overt hepatic steatosis and/or hepatic inflammation 
in chow-fed mice.  
 
Increased susceptibility to the development of HFD-
induced NAFLD with age   
 
To investigate whether aging may increase 
susceptibility to the development of HFD-induced 
NAFLD, 3- and 8-month-old mice were fed a HFD for 
12 weeks. While body weight was significantly 
increased in both young and middle-aged mice fed a 
HFD compared to mice fed a LFD (Fig. 3A), body 
weight was only marginally affected by aging in itself 
(Fig. 3A, HF young: 47.7 ± 0.7; HF aged: 54.4, p≤0.05). 
Moreover, liver to body weight ratio was significantly 
increased in middle-aged mice as compared to young 
mice fed a HFD (HF young: 2.1 ± 0.2; HF aged: 4.1 ± 
0.2, p≤0.05). H&E staining of liver sections of mice fed 
a HFD showed the predominant presence of 
microvesicular steatosis in HF-fed young mice in 
contrast to both macro- and microvesicular steatosis in 
HF-fed middle-aged mice (Fig. 3B). Consistent with 
enhanced lipid droplet formation in middle-aged versus 
young mice fed a HFD, hepatic TG content was 
significantly affected by the superimposed effect of 
aging and HFD-feeding, as shown by a three-fold 
increase in hepatic TG levels in middle-aged compared 
to young mice fed a HFD (Fig. 3C). In addition, 
despite an increase in Mcp1 expression levels, HFD-
feeding did not elevate inflammation in the livers of 
young mice (Fig. 3D and Sup. Fig.1B). However, 
HFD-feeding was associated with a significant 
increase in the mRNA expression levels of Tnf, Il10, 
Cxcl1 and Ikk2 (Fig. 3E) and in the phosphorylation 
status of Erk1/2 (Fig. 3F) in middle-aged mice. This 
pro-inflammatory phenotype was observed only in the 
livers of middle-aged mice. 
 
Aging alters the balance between lipid uptake and 
utilization in mice fed a HFD 
 
To identify mechanisms that may underlie this 
increased susceptibility to HFD-induced NAFLD, we 
first assessed CD36 expression levels in young and 
middle-aged mice fed a HFD for 12 weeks. CD36 
expression was significantly increased in these mice as 
















































Moreover, CD36 gene- and protein expression levels 
were significantly increased by the combined effects of 
age and HFD feeding (Fig. 4A-C), suggesting enhanced 
CD36-mediated hepatic fat uptake in middle-aged mice 
fed a HFD. As aging has also been shown to affect 
mitochondrial β-oxidation through alterations in the 
mitochondrial electron transport chain [25–27], we next 
assessed the protein level of the OXPHOS complexes in 
Figure 4. Increased CD36 expression in aged mice fed a
HFD  for  12  weeks.  (A)  qRT‐PCR  measurement  of  Cd36
transcript levels in livers of young and middle‐aged mice fed a
HFD  (versus  young  mice  on  LFD)  and  expressed  as  fold
induction.  (B)  Immunoblot analysis using anti‐CD36 and anti‐
tubulin antibodies was performed on liver extracts from young
and  middle‐aged  mice  fed  a  HFD.  (C)  Immunoblots  were
quantified by densitometry and normalized against tubulin as
a control for protein  loading. Values are expressed as mean ±
SEM;  n  =  6–8 mice  in  each  group. *  p≤0.05.  (nonparametric
Mann‐Whitney U test) 
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both young- and middle-aged mice fed a HFD. 
Although feeding mice a HFD did not alter the 
expression of OXPHOS complexes in young and 
middle-aged mice, a reduction was observed in the 
complexes I-IV in middle-aged compared to young 

















































dation in these mice. This, in combination with 
enhanced CD36-mediated lipid uptake, is likely to cause 
a severe disruption in the balance between fatty acid 
uptake and utilization in the livers of middle-aged mice, 




















































Figure 5.  Increased plasma membrane abundance of CD36  in aged mice  fed a HFD  is not  related  to Parkin
expression  levels.  (A) Representative blot and  (B)  Immunoblot analysis to  isolate plasma membrane  (M)  from cytoplasm
(Cyt) using anti‐CD36 antibody was performed in liver lysates from young and middle‐aged mice fed a LFD and HFD. Anti‐pan‐
Cadherin antibody was performed as a control for isolation purity and Actin antibody was performed as a control for protein
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Aging increases CD36 translocation in livers from 
mice fed a HFD for 12 weeks 
 
Since enhanced efficiency of FA uptake is directly 
related to increased recruitment of CD36 from 
intracellular storage sites toward the plasma membrane 
[15], we next isolated membrane (M) and cytoplasmic 
(Cyt) fractions from livers of young- and middle-aged 
mice fed a LFD and HFD and measured the plasma 
membrane abundance of CD36 using immunoblot 
analysis. CD36 expression was dramatically increased 
in the plasma membranes of middle-aged mice fed a 
HFD (Fig. 5A, B) suggesting enhanced CD36 
translocation in middle-aged mice on HFD. Since 
insulin has previously been demonstrated to induce 
CD36 translocation [28,29], we measured fasted insulin 
levels in young- and middle-aged mice fed a HFD. 
Plasma insulin levels were significantly increased in 
both young (LF: 0.077±0.19; HF: 0.66±0.09, P≤0.05) 
and middle-aged mice (LF: 0.18±0.02; HF: 1.34±0.15, 
P≤0.05) fed a HFD compared to mice fed a LFD. 
However, insulin levels were significantly increased in 
middle-aged mice compared to young mice fed a HFD. 
Parkin expression was assessed in both young and 
middle-aged mice fed a HFD as it has been reported to 
stabilize CD36 at the plasma membrane [30]. Parkin 
expression, however, was not altered in middle-aged 
mice fed a HFD compared to both groups: middle-aged 
mice fed a LFD (Fig. 5C) and young mice fed a HFD 




In this study, we explored the role of CD36 in the 
development of age-associated NAFLD. Consistent 
with pre-clinical data [18,20,21], we report for the first 
time that CD36 expression is positively associated with 
age in biopsies from patients with normal livers. In 
addition, CD36 expression was elevated in biopsies 
from patients with non-alcoholic steatosis (NAS). 
However, this increase in CD36 protein expression was 
not further elevated in aged NAS patients. Instead, aged 
NAS patients displayed enhanced plasma membrane 
expression of CD36 as compared to young NAS 
patients. This is suggesting that in elderly individuals 
with NAS, enhanced CD36 translocation may 
contribute to hepatic steatosis and NAFLD as opposed 
to absolute CD36 protein levels. In agreement with this, 
middle-aged mice exhibit an increased susceptibility to 
the development of HFD-induced NAFLD, which is 
mediated by an increased abundance of CD36 on the 
plasma membrane. Thus, our data indicate that 
enhanced CD36-mediated hepatic fat uptake may 
contribute to an accelerated progression of age-related 
NAFLD in both mice and humans.  
Our data are in line with previous findings confirming a 
role for CD36 in hepatic fatty acid uptake and hepatic 
steatosis in both rodents [18,31,32] and NAFLD 
patients [24]. Our data also extend previous findings on 
the pathogenic role of CD36 in the metabolic syndrome 
and age-related cardiomyopathy and lipotoxicity in 
heart and skeletal muscle [19–21] and suggest that 
CD36 is also one of the key candidate proteins playing a 
role in the development of age-related NAFLD. 
However, the mechanism(s) behind increased 
expression of CD36 in human and rodent livers is not 
known. Aging is associated with an increase in body 
weight and a physiological increase in lipid 
accumulation in non-adipose tissues [6]. In addition, 
aging increases the circulating levels of insulin, glucose 
and fatty acids in the human population and in mice 
[33], factors previously reported to either increase 
cellular CD36 expression or induce CD36 translocation 
to the plasma membrane [34–36]. As the patients in 
each age subgroup were matched in terms of sex 
distribution, body mass index, insulin resistance score 
(HOMA) and histological grade of steatosis (in the case 
of the NAS group), these parameters do not explain the 
differences seen in CD36 expression in our human 
study. Furthermore, not one single factor is likely to 
explain the age-related increase in hepatic CD36 levels 
in the normal liver group as we observed a significant 
increase in waist perimeter, glucose, AST and ALP 
levels between young and aged normal liver individuals 
(Table 1). In addition, we did not observe an age-effect 
on the hepatic CD36 expression level in NAS liver 
biopsy samples (Fig. 1). This is most likely due to the 
fact that CD36 expression levels were already 
significantly increased in biopsies from young NAS 
livers as compared with those from young normal 
livers. However, in young NAS patients, CD36 
immunoreactivity was restricted mainly to the 
cytoplasm of hepatocytes, whereas in aged NAS 
patients, CD36 staining was largely detected at the 
plasma membrane of liver cells (Fig. 1, lower panels, 
inserts). Nevertheless, we cannot exclude the possibility 
that this membraneous staining pattern of CD36 might 
be related to accumulation of fat in the cytoplasm that 
may have pushed CD36 to the side; the factors 
responsible for the increased membrane abundance of 
CD36 in aged NAS patients remain elusive and further 
studies are required. Of all parameters tested only ALP 
was significantly increased in aged versus young NAS 
livers, but its level was within the normal clinical range. 
Further studies are clearly needed to explain the 
increased translocation of CD36 in aged NAS patients.  
Increased hepatic CD36 membrane expression was 
predominantly observed in middle-aged mice fed a 
HFD. The mechanism by which CD36 is translocated to 
the plasma membrane has not yet been elucidated. 
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However, it has been demonstrated that CD36 can be 
translocated rapidly from intracellular sites to the 
plasma membrane in response to insulin and thereby 
enhance FA uptake [28]. Therefore, the enhanced 
CD36 membrane expression in HF-fed middle-aged 
mice may be related to significantly enhanced plasma 
insulin levels in middle-aged compared to young mice 
fed a HFD. Indeed, insulin levels were elevated 7.5-
fold in middle-aged mice fed a HFD in comparison to 
a 1.5-fold increase in the young mice. This may have 
contributed to a strong lipogenic drive with age, 
explaining not only the increased membrane 
abundance of CD36 but also the increased hepatic 
steatosis following HF-feeding in middle-aged mice 
(Fig. 3B and C). In addition, increased plasma insulin 
levels have also been observed in senescence-prone 
(SAMP10) mice and reported to explain the increased 
lipid accumulation with age in these mice [11]. 
However, since cytokines have been demonstrated to 
regulate CD36 expression at the transcriptional level 
[37], the possibility also arises that increased cytokine 
levels during hepatic inflammation (Fig. 3F) are 
responsible for the enhanced CD36 membrane 
abundance observed in middle-aged mice fed a HFD 
(Fig. 5A, B). Consistent with this is the hepatic 
overexpression of CD36 in NASH patients and in 
those with chronic HCV G1 infection [24]. 
Nevertheless, we cannot exclude the role of other 
mechanisms such as reduced CD36 recycling resulting 
in a delay in the proteasomal degradation of CD36 
[38]. Indeed, CD36 turnover has been shown to be 
abnormally slow in macrophages from insulin-resistant 
ob/ob mice, resulting in CD36 accumulation at the 
plasma membrane [39]. In line with this, insulin has 
been shown to reduce CD36 ubiquitination and 
enhance CD36 protein levels in CHO cells expressing 
both the insulin receptor and CD36 [38]. As this was 
associated with enhanced fatty acid uptake, it may 
provide an alternative mechanism for trapping CD36 
at the membrane surface. Furthermore, Parkin is 
suggested to play a pivotal role in enhancing hepatic 
fat uptake by increasing the protein stability and half-
life of CD36 through monoubiquitination of CD36 
[30]. However, we did not observe an age- or HFD-
associated increase in Parkin expression in middle-
aged mice compared to young mice. Nevertheless, 
more recent work has shown that neddylation of 
Parkin increases E3 ligase activity without affecting 
expression [40]. This may be an alternative pathway 
leading to increased mono-ubiquitination of CD36 and 
stabilization at the plasma membrane and warrants 
further study. Altogether, the exact mechanism by 
which CD36 is translocated to the plasma membrane 
has not been fully elucidated and needs further 
investigation. 
In addition to our data implicating CD36 in age-induced 
NAFLD, we also report that middle-aged mice show a 
decline in the protein expression levels of the 
mitochondrial electron transport chain protein 
expression (complex I-IV), suggesting that fat oxidation 
is impaired in middle-aged mice irrespective of HF-
feeding. Although we did not perform direct 
measurements of fatty acid oxidation, this is in line with 
a previous study showing that mitochondria of middle-
aged mice display many electron transport chain defects 
and decreased complex I and IV activities [41]. Our 
results may thus suggest that the CD36-mediated 
increase in hepatic fat uptake in HFD-fed middle-aged 
mice, coupled with a decrease in fat oxidation in the 
liver, will enhance triglyceride synthesis in the liver 
during aging and thus may be key to advancing NAFLD 
with aging.  
 
Furthermore, our results indicate that minor lipid 
droplet formation is indeed present in middle-aged mice 
fed a regular chow diet for one year (Fig. 2D). 
However, the livers of these mice did not accumulate 
more TG (Fig. 2E) and failed to show hepatic 
inflammation (Fig. 2F, Sup. Fig. 1A), indicating the 
absence of NAFLD. Moreover, NAFLD development 
(hepatic steatosis and inflammation) occurred only in 
middle-aged mice fed a HFD (Fig. 3). Our data thus 
suggest that the aging process in itself does not 
accelerate NAFLD development in the rodent liver; 
however, aging does greatly promote the development 
of hepatic steatosis and inflammation (NAFLD) when 
superimposed with a HFD. Since hyperinsulinemia, 
steatosis and inflammation are considered as systemic 
manifestations of cellular hyperfunction or overactivity 
[42,43], our findings are consistent with the 
hyperfunction theory of aging proposed by 
Blagosklonny, which postulates that processes 
contributing to growth and reproduction run on in later 
life, leading to pathology and eventually to death 
[42,43]. 
 
Although our findings seem to contradict the current 
understanding that aging is associated with hepatic 
steatosis in humans and rodents, they are in line with 
the recent study of Fontana [14], who showed that aged 
mice are more prone to develop diet-induced steato-
hepatitis than young mice. Significantly, the authors did 
not find a difference in the development of hepatic 
steatosis between 6-, 12- and 22-month-old mice fed a 
HFD for 16 weeks [14]. Although the authors did not 
study the effect of aging on hepatic lipid accumulation 
in chow fed mice, this clearly contrasts with our 
observation that HF-feeding when super-imposed on 
middle-aged mice does significantly promote hepatic 
steatosis. The reason for this discrepancy is not clear; it 
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may, however, be related to the extended length of the 
dietary period in the study of Fontana et al. [14]. This 
could explain the lower accumulation of hepatic lipid 
levels in the young mice fed a HFD in our study. 
 
In summary, we have shown that aging per se does not 
contribute to the development of NAFLD; however, it 
does increase susceptibility to the development of diet-
induced NAFLD. Furthermore, we report for the first 
time that aging increases CD36 membrane expression in 
the livers of both mice and humans. Therefore we 
propose that increased CD36 localization/stabilization 
at the plasma membrane may be a key to enhanced 
hepatic fat uptake, and may play an important role in 
advancing NAFLD with age. Our results suggest that 
drugs that prevent the increase in CD36 expression 
and/or CD36 from anchoring at the plasma membrane 
may alleviate NAFLD and prevent the transition from 
benign steatosis toward more advanced NASH.  
 
EXPERIMENTAL PROCEDURES  
 
Patients. This study comprised 56 non-diabetic patients 
who underwent a needle liver biopsy during 
programmed laparoscopic cholecystectomy. Liver 
biopsy sections were collected as previously described 
[24] and histological diagnosis of NAFLD according to 
Brunt et al [44] was used to select patients with 
histologically normal livers (grade 0, < 5% of steatotic 
hepatocytes; n=30) or with simple steatosis (NAS, 
grades 1 and 2, 5 to 66% of steatotic hepatocytes; 
n=26). Each group was further classified according to 
distinct age categories, resulting in a young subgroup 
aged 20-42 years (normal liver: n=16, NAS: n=11) and 
an older subgroup aged 50-83 years (normal liver: 
n=14; NAS: n=15). Patients in each age subgroup were 
matched in terms of sex distribution, BMI, insulin 
resistance score (HOMA) and histological grade of 
steatosis (in the case of NAS group). Since hepatic 
inflammation is a confounding variable [24], NASH 
patients were excluded from the study. Additional 
standard exclusion criteria were: patients with an 
alcohol intake of more than 20 gram/day, those with 
chronic hepatitis B, C or HIV infections, and patients 
taking chronic medications. The study was performed in 
agreement with the Declaration of Helsinki and with 
local and national laws. The Human Ethics Committee 
of the University Hospital Santa Cristina (Madrid, 
Spain) approved the study procedures, and each patient 
provided written informed consent before inclusion in 
the study. 
 
Immunohistochemistry on human liver biopsy sections. 
Immunostaining and computational image analysis 
using analySIS® software (Soft Imaging System, 
Gmbh, Münster, Germany) were performed on 
formalin-fixed paraffin-embedded liver biopsy sections 
(4 m thickness) from all patients of each group, as 
previously described [24]. All immunostained liver 
biopsy sections were first coded and then evaluated by 
an expert in liver immunohistochemistry (CG-M). By 
measuring the stained surface in 6 different lobular 
areas, an average score representing the percentage of 
liver tissue area occupied by CD36 staining was 
obtained. In order to more accurately evaluate the 
expression of CD36 restricted to hepatocytes, we 
measured CD36 staining by using a high magnification 
objective (40x) (Nikon, Tokyo, Japan) to focus on 
lobular areas where hepatocytes are the predominant 
cell type. For each liver biopsy, the average value was 
considered as the hepatic CD36 expression index and 
expressed as the percentage of lobular area occupied by 
CD36 staining.  
 
Clinical and laboratory assessment. After a 12 h 
overnight fast, clinical and anthropometric data as well 
as venous blood samples were obtained from each 
patient at the time of liver biopsy. All serum chemistry 
analyses were performed at the Central Laboratory 
Service of the University Hospital Santa Cristina 
(Madrid, Spain) as described [24]. Insulin resistance 
was calculated by the homeostasis model assessment 
(HOMA-IR) [45]. Antibodies against (hepatitis B, C 
and HIV) surface antigens were tested for by 
immunoenzymatic assays (Murex, Dartford, UK) and 
were used to exclude patients from the study. 
 
Mice. This study was performed with the approval of 
the University of Alberta Animal Policy and Welfare 
Committee and the University of Groningen Ethics 
Committee for Animal Experiments, which adheres to 
the principles and guidelines established by the 
European Convention for the Protection of Laboratory 
Animals. Experiments were carried out on young (12-14 
week old) and middle-aged (52-58 week old) male 
C57BL6/J mice, maintained on a 12-hour light-dark 
cycle and given free access to water and chow diet 
unless otherwise stated. At 12-14 or 32-34 weeks of 
age, a subset of mice was randomly divided into a low-
fat diet (LFD) group (D12450B, 10% kcal from fat, 
Research Diets) and a high-fat diet (HFD) group 
(D12492, 60% kcal from fat, Research Diets) for a 
period of 12 weeks. Insulin was measured in plasma 
from fasted mice as described [20].  
 
Liver histology. Paraffin-embedded sections of the liver 
(4µm) were stained with hematoxylin-eosin (H&E). 
Microscopy was performed with a Leica DM 3000 
microscope with a DFC420 camera (Leica 
Microsystems, Rijswijk, the Netherlands).  
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Quantitative real-time(qRT) PCR— Hepatic gene 
expression analyses. Total RNA was isolated from the 
liver using QIAazol reagent (QIAGEN, Venlo, the 
Netherlands). First-strand cDNA synthesis was 
performed using the QuantiTect Reverse Transcription 
Kit (QIAGEN, Venlo, the Netherlands). qRT-PCR was 
performed using a 7900HT System (Applied 
Biosystems, Warrington, UK) and values were 
corrected using the housekeeping gene Cyclophillin A 
(Ppia). Primers are presented in Supplemental Table 1.  
 
Determination of liver triglycerides. Crushed liver 
tissues from fasted mice were homogenized, lipids 
extracted and the amount of triglyceride determined by 
gas-liquid chromatography as previously described [46].  
 
Immunoblot analysis. Liver tissue was homogenized 
and equal amounts of protein were subjected to SDS-
PAGE, transferred to nitrocellulose or PVDF membrane 
(Amersham, Buckinghamshire, UK) and immunoblotted 
with antibodies against, Erk1/2, p-Erk1/2, Actin, α-
tubulin, Parkin (Cell Signaling Technology, Leiden, the 
Netherlands), Pan Cadherin (Abcam, Cambridge, UK), 
CD36 (Novus Biologicals, Littleton, USA) and Oxphos 
(Abcam, Cambridge, UK; a kind gift from Dr. Herman 
Sillje, UMCG, Groningen). Immuno-positive bands 
were visualized by chemiluminescence (GE Healthcare 
Life Sciences, Diegem, Belgium) and quantified using 
the Molecular Imager ChemiDoc xrs+system from Bio-
Rad (Veenendaal, the Netherlands). 
 
Statistical analysis. Data are presented as mean ± SEM 
unless stated otherwise. The characteristics of the 
patients studied were compared by the Pearson 2 test or 
Fisher exact test for categorical variables and the 
unpaired t test or Mann-Whitney U test for continuous 
variables. Spearman’s rho test was used to evaluate 
correlations. Experimental data were compared using 
the unpaired t test or Mann–Whitney U test. The level 
of significance was set at P<0.05. All statistical analyses 
were performed in GraphPad Prism (v. 5.00 for 
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Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
Ikk2 GGAGTACTGCCAAGGAGGAGAT ACAGGCTGCCAGTTAGGGAGGAAG 
IkBα TGGAAGTCATTGGTCAGGTGAA CAGAAGTGCCTCAGCAATTCCT 
Cd68 TGACCTGCTCTCTCTAAGGCTACA TCACGGTTGCAAGAGAAACATG 
CxcL1 CCAAACCGAAGTCATAGCCAC GTCTTCTTTCTCCGTTACTTGG 
Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 
Il-1β TGCAGCTGGAGAGTGTGG TGCTTGTGAGGTGCTGATG 
Il-6 GTTCTCTGGGAAATCGTGGA TTTCTGCAAGTGCATCATCG 
Mcp1 GCTGGAGAGCTACAAGAGGATCA ACAGACCTCTCTCTTGAGCTTGGT 
Cd36 GATCGGAACTGTGGGCTCAT GGTTCCTTCTTCAAGGACAACTTC 
Tnf GTAGCCCACGTCGTAGCAAAC AGTTGGTTGTCTTTGAGATCCATG 
Ppia TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG 
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Supplementary  Figure  1.  Hepatic  inflammation  did  not
altered in the aged mice fed a chow diet and young mice fed
with HFD for 12 weeks. (A) Phosphorylation status of Erk1/2 was
detected  in  liver  extracts  from  young  and middle‐aged mice using
immunoblot  analysis.  (B)  Immunoblot  analysis using  anti‐phospho‐









as  a  control  for  loading.  Values  are  expressed  as  mean  ±  SEM;  n=  6‐7 
mice/group. *p≤ 0.05. (Nonparametric Mann‐Whitney U test). 
